Joining with the Association for Clinical Oncology (ASCO) and 45 other state societies, MSCO signed onto a Congressional letter urging lawmakers to protect our nation's cancer patients by taking steps to mitigate cancer drug shortages.

As you know, ASCO has been advocating for Congress to take action, urging House and Senate leadership to enact the following recommendations:

• Address economic factors that drive generic manufacturers out of the market and consider stabilizing the market with long-term contracts and guaranteed prices.

• Reward reliable U.S. manufacturing of critical and supportive medications through price stabilization and investment in continuous manufacturing or other advanced manufacturing.

• Recognize potential shortages earlier by increasing the FDA’s visibility into the supply chain so the agency can predict and respond to potential shortages earlier.

• Relay information about potential shortages to health systems and providers to help them prepare for and mitigate possible supply challenges.